BioSpace News Archive

Neuralgia is caused due to damage of nerves. The condition is characterized by an abnormal symptom with effects like sharp, burning, and mostly severe pain.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Immunodeficiency disorders prevent a body from fighting infections and diseases. Immunodeficiency disorders are either congenital or acquired.

Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as “Dr. Reddy’s”), announced today that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy’s will sell its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BioDelivery Sciences International, Inc. (BDSI).

Prevalence of various types of cancers such as breast, prostate, and lung cancer, development of biological & targeted drug therapies, and reliability of cancer biomarkers fuel the growth of the global cancer biomarkers market.

Increasing count of amputees, patients with auditory loss, dental problems, and increasing availability of biocompatible materials.

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has scheduled a webinar on Thursday, August 5, 2021 at 10:00 a.m. Eastern Time to discuss the Complete Response Letter (CRL) that the Company’s licensor, medac GmbH, recently received from the Food and Drug Administration (FDA) for treosulfan.

In a proof-of-concept study, researchers at Children’s Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.

Today, Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray® PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer.